Zuranolone (Zurzuvae)

What it treats

Zuranolone is approved by the U.S. Food and Drug Administration to treat postpartum depression in adults.

Off-label use is limited given how new the drug is and how targeted the labeled indication is. Off-label means a purpose the label doesn't formally list even though evidence and practice support it.

How it works

Zuranolone is chemically similar to allopregnanolone, a natural neurosteroid the body makes from progesterone. Allopregnanolone acts on GABA-A receptors, one of the brain's main calming systems.

After delivery, allopregnanolone levels drop rapidly. That drop is thought to play a specific role in postpartum depression. Zuranolone acts on the same receptors and, taken as a 14-day course, appears to reset that signaling enough to relieve depression for many patients.

Receptor mechanism (detail)

Zuranolone is an oral synthetic allopregnanolone analog and a positive allosteric modulator of both synaptic and extrasynaptic GABA-A receptors. Extrasynaptic (tonic) GABA-A activity is what benzodiazepines don't reach, and it's thought to be central to the effects of neurosteroid modulators in postpartum depression. Unlike benzodiazepines, zuranolone is dosed as a defined 14-day pulse rather than chronic use.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual.

Fixed dose: 50 mg once nightly for 14 days, taken with a fat-containing meal in the evening.

Dose reduction to 40 mg per day is recommended in the presence of moderate or severe hepatic impairment, severe renal impairment, or concomitant use of strong CYP3A4 inhibitors.

Safety monitoring

• Sedation. Zuranolone causes CNS depression. No driving or operating heavy machinery for at least 12 hours after each dose.
• Fetal harm signal. Contraception is required during treatment and for at least one week after the last dose.
• Suicidality in the first weeks (FDA boxed warning for antidepressants applies).
• Breastfeeding. Transfer into milk occurs; risks and benefits are individualized.
• Concomitant CNS depressants. Alcohol, opioids, and benzodiazepines add to sedation.

What to expect

Common side effects

Common side effects include:

• Sedation.
• Dizziness.
• Headache.
• Diarrhea.
• Fatigue.
• Sedation-related fall risk in some.

If a side effect is severe, that's a conversation to have with the prescriber rather than a reason to stop on your own.

Serious side effects and warnings

Boxed warning: Driving impairment. Zuranolone can cause significant CNS depression. Do not drive or operate heavy machinery for at least 12 hours after each dose. Impairment can occur even without a subjective feeling of sedation.

• Suicidality. Standard antidepressant monitoring applies, particularly under age 25.
• Fetal harm. Contraception is required during and for at least one week after the course.
• CNS depression stacking with alcohol, benzodiazepines, or opioids.

Sexual side effects

Sexual side effects aren't a prominent feature of the 14-day course.

Weight, appetite, and sleep

Weight and appetite effects are not a typical feature of the short course. Sleep is often deeper because of the sedative effect during the 14 days.

Starting and dosing basics

This section is general background, not a dosing instruction for any individual. The right plan is a decision for a prescriber.

Zuranolone comes as a capsule taken with a fat-containing meal in the evening (helps absorption and lets sedation land at night). The full course is 14 days. Dose reductions apply for liver or kidney impairment and for strong CYP3A4 inhibitors.

Missed doses and interactions

If you miss a dose, take it as soon as you remember on the same day, with food. If it's the next day, skip the missed dose and take the next scheduled dose. Don't take two doses at once.

Interactions matter. Alcohol, benzodiazepines, and opioids add to sedation. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) raise zuranolone levels; a lower zuranolone dose may be used. Strong CYP3A4 inducers (rifampin, carbamazepine) lower levels. Give every prescriber and pharmacist a full list of your medications and supplements, including over-the-counter ones.

Stopping and tapering

The 14-day course is designed to be stopped at the end without a taper. Ongoing treatment for depression (continuing a longer-term antidepressant, psychotherapy) is often planned alongside the course, in case the benefit doesn't fully hold.

Pregnancy and breastfeeding

Because zuranolone is used specifically postpartum, breastfeeding is central. The drug enters breast milk, and effects on the nursing infant are not fully characterized. Some patients pump and discard during the course; others continue nursing after weighing risks and benefits with a pediatrician. Contraception is required during and for at least a week after the last dose because of a fetal harm signal in animal studies.

Cost and generic availability

Zuranolone is brand-only (Zurzuvae). Cost is high; insurance coverage typically requires prior authorization. Manufacturer assistance programs may be available.

Common questions

How is zuranolone different from brexanolone? Both are neurosteroid GABA modulators for postpartum depression. Brexanolone is a 60-hour continuous IV infusion in a certified clinic under REMS. Zuranolone is an oral capsule taken at home once nightly for 14 days. For most patients, zuranolone's format is easier to implement.

How fast does it work? Many patients notice improvement within 3 to 14 days. That's much faster than a typical SSRI course.

Why is the course only 14 days? Clinical trials found that a 14-day pulse produced sustained benefit for many patients, without needing chronic dosing. It's a different model from most antidepressants.

Can I breastfeed? It's possible, though the drug does enter milk. Practice varies; the pediatrician and prescriber can help plan.

Why can't I drive? Zuranolone causes CNS depression that can impair driving even when a person doesn't feel obviously drowsy. No driving for at least 12 hours after each dose.

Questions to ask your prescriber

• Am I a candidate for zuranolone, and would brexanolone fit better?
• How do we plan around breastfeeding?
• What contraception do I need, and for how long after?
• What ongoing depression treatment happens after the 14 days?
• What insurance coverage or manufacturer support is available?

Sources

This guide draws on current prescribing information and public health references and current as of June 8, 2026. It is reviewed for clinical accuracy and updated as guidance changes.

• U.S. Food and Drug Administration. Zuranolone (Zurzuvae) prescribing information (2023 approval).
• MedlinePlus, U.S. National Library of Medicine. Zuranolone.
• American College of Obstetricians and Gynecologists. Screening for and treatment of perinatal depression.
• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder.